Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

March 18, 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

March 11, 2024

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

March 11, 2024

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

March 04, 2024

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

March 04, 2024

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

February 26, 2024

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

February 26, 2024

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

February 21, 2024

Jonathan Constance, PhD, and his team have created a digital pharmacology platform for assessing drug dynamics directly among children with cancer.

February 19, 2024

Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.

February 07, 2024

Huntsman Cancer Institute introduces the first and only single-port robot in the Mountain West for head and neck surgical oncology patients.

January 23, 2024

Huntsman Cancer Institute has appointed new roles for Theresa Werner, MD, and Neeraj Agarwal, MD, FASCO.

January 14, 2024

Doctors diagnosed Christopher Gregg, PhD, with stage IV metastatic breast cancer in 2018. Then, he started thinking of ways to improve his treatment.

January 10, 2024

Alana Welm, PhD, received the 2023 American Association for Cancer Research Outstanding Investigator Award for Breast Cancer Research.

January 04, 2024

The oral XPO1 inhibitor selinexor in combination with ruxolitinib was associated with a tolerable and manageable adverse effect profile and elicited signals of clinical efficacy in patients with JAK inhibitor–naive myelofibrosis.

December 27, 2023

Researchers at Huntsman Cancer Institute at the University of Utah discovered that the level of blood and immune cells in mouse model offspring would fluctuate based on the amount of folic acid consumed by their mothers during pregnancy.

December 23, 2023

Researchers at University of Utah Health have designed new digital tools that use relevant information from patient health records to prompt doctors to consider lung cancer screening for high-risk patients and provide personalized guidance on screening.

December 22, 2023

WebMD awarded Huntsman Cancer Institute at the University of Utah its highest honor, the 2023 WebMD Elite Choice Award.

December 19, 2023

Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.

December 19, 2023

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

December 12, 2023

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.